Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

This study has been terminated.
(Publication of data from a similar study made the current study redundant.)
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: March 3, 2010
Last updated: November 22, 2011
Last verified: November 2011
The purpose of the present study was to evaluate the addition of aliskiren, to amlodipine can attenuate ankle edema formation in hypertensive patients.

Condition Intervention Phase
Ankle Edema
Drug: Aliskiren/amlodipine
Drug: Amlodipine
Drug: Placebo to Aliskiren/amlodipine
Drug: Placebo to Amlodipine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Parallel Study to Assess the Effects of Aliskiren/Amlodipine and Amlodipine Monotherapy on Ankle Foot Volume (AFV) in Patients naïve to Trial Drugs With Mild to Moderate Hypertension

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change in the Ankle Foot Volume (AFV) as Measured by Displacement Method [ Time Frame: Baseline, 4 weeks ]
    AFV (mL) was measured using the principle of water displacement using a commercially available foot volumeter. The amount of water displaced in milliliters (mL) equals the volume of the foot/ankle. The study was terminated due to the publication of the results of a near identical study by Fogari et al. Hence, for the current study, no analysis was performed.

Enrollment: 31
Study Start Date: February 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aliskiren/amlodipine + Placebo to amlodipine

During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.

The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.

Drug: Aliskiren/amlodipine
Aliskiren/amlodipine 150/5 mg/day
Other Name: SPA100
Drug: Placebo to Amlodipine
Placebo to Amlodipine 5 mg/day
Active Comparator: Amlodipine + Placebo to aliskiren/amlodipine

During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.

The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.

Drug: Amlodipine
Amlodipine 5 mg/day.
Drug: Placebo to Aliskiren/amlodipine
Placebo to Aliskiren/amlodipine 150/10 mg/day


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients (male or female) with hypertension aged between 18-75 yrs.
  • Patients not treated with amlodipine or no amlodipine in previous 1 year.
  • Post-menopausal females

Exclusion Criteria:

  • Patients unable to switch from prior hypertensive medication.
  • Severe hypertension.
  • Pregnant or nursing females.
  • Patients with Type 1 or Type 2 diabetes mellitus
  • History of immunodeficiency diseases, including a positive Human immunodeficiency virus (HIV) (Enzyme-linked immunosorbent assay [ELISA] and Western blot) test result.
  • A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

Other protocol-defined inclusion/exclusion criteria are applied

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01080768

Novartis Investigative Site
Beek en Donk, Netherlands
Novartis Investigative Site
Bosch, Netherlands
Novartis Investigative Site
Den Haag, Netherlands
Novartis Investigative Site
Hoogwoud, Netherlands
Novartis Investigative Site
Lichtenvoorde, Netherlands
Novartis Investigative Site
Lieshout, Netherlands
Novartis Investigative Site
Poortvliet, Netherlands
Novartis Investigative Site
Utrecht, Netherlands
Novartis Investigative Site
Wildervank, Netherlands
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01080768     History of Changes
Other Study ID Numbers: CSPA100A2201
2009-014359-63 ( EudraCT Number )
Study First Received: March 3, 2010
Results First Received: November 22, 2011
Last Updated: November 22, 2011

Keywords provided by Novartis:
Pedal edema

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents processed this record on April 28, 2017